journal
MENU ▼
Read by QxMD icon Read
search

Hematological Oncology

journal
https://www.readbyqxmd.com/read/28913957/autologous-peripheral-blood-stem-cell-transplantation-and-the-role-of-lenalidomide-in-patients-affected-by-poems-syndrome
#1
REVIEW
Francesco Autore, Idanna Innocenti, Marco Luigetti, Nicola Piccirillo, Federica Sora, Patrizia Chiusolo, Simona Sica, Andrea Bacigalupo, Luca Laurenti
POEMS syndrome is a rare paraneoplastic condition, with a poorly understood pathogenesis. High dose chemotherapy followed by autologous stem cell transplantation (ASCT) has been reported to be an effective therapeutic option for patients with good performance status. Here, we review the role of ASCT for POEMS syndrome and discuss indications together with advantages and disadvantages, and related issues such lenalidomide given before or after ASCT, VEGF levels as a marker of disease, and different regimens for stem cell mobilization...
September 15, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28850694/splicing-variant-profiles-and-single-nucleotide-polymorphisms-of-the-glucocorticoid-receptor-gene-in-relation-to-glucocorticoid-sensitivity-of-b-cell-precursor-acute-lymphoblastic-leukaemia
#2
Meixian Huang, Takeshi Inukai, Keiko Kagami, Masako Abe, Tamao Shinohara, Atsushi Watanabe, Shinpei Somazu, Hiroko Oshiro, Kumiko Goi, Hiroaki Goto, Masayoshi Minegishi, Shotaro Iwamoto, Kevin Y Urayama, Kanji Sugita
Glucocorticoid (GC) shows antileukaemic activity via binding to the GC receptor (GR). The human GR gene has 4 splicing variants besides the functional isoform GRα, but their significance in GC sensitivity of acute lymphoblastic leukaemia (ALL) has been inconsistent. Additionally, several studies evaluated the relevance of GR gene single nucleotide polymorphisms (SNPs) in the GC sensitivity of ALL, but the current cumulative evidence appears inconclusive. Addressing limitations in previous studies, we used a large series of B-cell precursor ALL (BCP-ALL) cell lines established from Japanese patients to comprehensively examine all 5 splicing variants of the GR gene and candidate SNPs, and their association with GC-sensitivity...
August 29, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28840598/therapeutic-monoclonal-antibodies-in-combination-with-pomalidomide-can-overcome-refractoriness-to-both-agents-in-multiple-myeloma-a-case-based-approach
#3
Marc-Andrea Baertsch, Michael Hundemer, Jens Hillengass, Hartmut Goldschmidt, Marc S Raab
In multiple myeloma (MM), the synergy between immunomodulatory drugs (IMiDs) and monoclonal antibodies (MABs) has been demonstrated in several pivotal trials. However, disease refractory to either class of compounds remains a major therapeutic challenge. We here report on 3 heavily pretreated MM patients who were refractory to pomalidomide as well as to MABs against CD38 (daratumumab) or CD20 (rituximab), respectively, but who responded to retreatment with the same agents in combination. Responses were durable with PFS of 7, 10 (ongoing), and 30 months from initiation of combination treatment...
August 25, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28833354/immunohistochemical-expression-of-cereblon-and-mum1-as-potential-predictive-markers-of-response-to-lenalidomide-in-extranodal-marginal-zone-b-cell-lymphoma-of-the-mucosa-associated-lymphoid-tissue-malt-lymphoma
#4
Barbara Kiesewetter, Ingrid Simonitsch-Klupp, Christoph Kornauth, Werner Dolak, Julius Lukas, Marius E Mayerhoefer, Markus Raderer
Lenalidomide is an active agent for the treatment of MALT lymphoma. Recently, high expression levels of cereblon (CRBN) and MUM1 have been associated with better response rates in multiple myeloma treated with lenalidomide. However, there are no data on CRBN and MUM1 expression in MALT lymphoma. In the current study, we have systematically investigated a potential correlation of CRBN/MUM1 immunohistochemical expression and response to lenalidomide-based therapy in a series of 46 patients with MALT lymphoma treated at the Medical University Vienna 2009 to 2014...
August 22, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28791712/feasibility-of-myeloablative-allogeneic-hematopoietic-cell-transplantation-from-unrelated-donors-for-patients-with-relapsed-or-refractory-multiple-myeloma
#5
LETTER
Sumito Shingaki, Nobuhiro Tsukada, Tadao Ishida, Kenshi Suzuki
No abstract text is available yet for this article.
August 8, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28786198/il17a-and-il23r-gene-polymorphisms-affect-the-clinical-features-and-prognosis-of-patients-with-multiple-myeloma
#6
Tetsuhiro Kasamatsu, Mari Kimoto, Noriyuki Takahashi, Yusuke Minato, Nanami Gotoh, Makiko Takizawa, Morio Matsumoto, Morio Sawamura, Akihiko Yokohama, Hiroshi Handa, Norifumi Tsukamoto, Takayuki Saitoh, Hirokazu Murakami
Single nucleotide polymorphisms (SNPs) in interleukin 17 (IL17A) and IL-23 receptor (IL23R) are involved in the pathogenesis of many cancers and autoimmune diseases. We investigated the influence of IL17A and IL23R SNPs on the risk of developing multiple myeloma (MM) and its clinical features. We obtained genomic DNA from 120 patients with MM and 201 healthy controls and detected IL17A -197 G/A (rs2275913) and IL23R H3Q (rs1884444) genotypes using the polymerase chain reaction-restriction fragment length polymorphism method...
August 7, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28771763/farmarel-an-italian-pharmacovigilance-project-to-monitor-and-evaluate-adverse-drug-reactions-in-haematologic-patients
#7
Nicola S Fracchiolla, Silvia Artuso, Agostino Cortelezzi, Anna M Pelizzari, Paola Tozzi, Maurizio Bonfichi, Federica Bocchio, Livio Gargantini, Elisa De Rosa, Giuseppe D Vighi, Lucia Prestini, Simona Sammassimo, Niccolò Frungillo, Maria C Pasquini, Alessandra Ragazzi, Daniele Boghi, Alessia Pastore, Eraldo Lanzi, Giuseppe Gritti, Giulia Quaresmini, Simone Voltolini, Roberta Gaiardoni, Consuelo Corti, Maria C Vilardo, Maria L La Targia, Giacomo Berini, Massimo Magagnoli, Claudia Bacci, Dario Consonni, Alma L Rivolta, Giuliana Muti
Adverse drug reactions (ADRs) reduce patients' quality of life, increase mortality and morbidity, and have a negative economic impact on healthcare systems. Nevertheless, the importance of ADR reporting is often underestimated. The project "FarmaREL" has been developed to monitor and evaluate ADRs in haematological patients and to increase pharmacovigilance culture among haematology specialists. In 13 haematology units, based in Lombardy, Italy, a dedicated specialist with the task of encouraging ADRs reporting and sensitizing healthcare professionals to pharmacovigilance has been assigned...
August 3, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28752619/spectrum-and-immunophenotyping-of-653-patients-with-b-cell-chronic-lymphoproliferative-disorders-in-china-a-single-centre-analysis
#8
Yi Miao, Lei Cao, Qian Sun, Xiao-Tong Li, Yan Wang, Chun Qiao, Li Wang, Rong Wang, Hai-Rong Qiu, Wei Xu, Jian-Yong Li, Yu-Jie Wu, Lei Fan
The incidence of B-cell chronic lymphoproliferative disorders (B-CLPDs) is significantly lower in China than that in western countries. There have been studies involving small cohorts with conflicting results regarding the spectrum of B-CLPDs in China, and the types and immunophenotyping of B-CLPDs in China remain largely unexplored. We conducted a retrospective analysis of 653 cases of B-CLPDs seen in our centre from 2011 to 2015. Four-colour flow cytometry was used to determine the expression of each immunological marker, and the diagnostic values of the immunological markers were also investigated...
July 28, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28744882/epstein-barr-virus-positivity-is-associated-with-angiogenesis-in-and-poorer-survival-of-patients-receiving-standard-treatment-for-classical-hodgkin-s-lymphoma
#9
Young Wha Koh, Jae-Ho Han, Dok Hyun Yoon, Cheolwon Suh, Jooryung Huh
Epstein-Barr virus (EBV) is a significant contributor to the development of classical Hodgkin's lymphoma (cHL). Recent studies have documented associations between angiogenesis and EBV-associated malignancies. No study has yet examined the associations among, and prognostic implications of, EBV infection, vascular endothelial growth factor (VEGF) expression, and microvessel density (MVD) in cHL patients. Diagnostic tissues from 135 cHL patients treated with adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) were retrospectively evaluated by in situ hybridization of EBV-encoded small RNA (EBER) and immunohistochemical staining for VEGF and CD31 (a measure of MVD)...
July 26, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28736928/mean-platelet-volume-predicts-prognosis-in-patients-with-diffuse-large-b-cell-lymphoma
#10
Shujuan Zhou, Yongyong Ma, Yifen Shi, Liyuan Tang, Zhouyi Zheng, Fang Fang, Jianhua Feng, Yu Zhang, Lan Sun, Yi Chen, Bin Liang, Songfu Jiang, Zhijian Shen, Kang Yu, Siqian Wang
To determine the prognostic value of baseline mean platelet volume (MPV) in diffuse large B-cell lymphoma (DLBCL) patients. We retrospectively analyzed 161 DLBCL patients who received R-CHOP chemotherapy. The associations between MPV and clinicopathological factors were assessed. A low MPV (MPV ≤ 9.1 fl, cut-off was calculated by receiver operating characteristics) was associated with any other clinicopathological factors. Patients with MPV ≤ 9.1 fl experienced a shorter progression-free survival (PFS) (2-year PFS rate, 60...
July 23, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28730742/microenvironment-modulation-and-enhancement-of-antilymphoma-therapy-by-the-heparanase-inhibitor-roneparstat
#11
LETTER
Anna Rossini, Franco Zunino, Giusi Ruggiero, Michelandrea De Cesare, Denis Cominetti, Monica Tortoreto, Cinzia Lanzi, Giuliana Cassinelli, Roberta Zappasodi, Claudio Tripodo, Alessandro Gulino, Nadia Zaffaroni, Massimo Di Nicola
No abstract text is available yet for this article.
July 21, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28707346/relationship-between-response-rates-and-median-progression-free-survival-in-non-hodgkin-s-lymphoma-a-meta-analysis-of-published-clinical-trials
#12
Naveen Mangal, Ahmed Hamed Salem, Mengyao Li, Rajeev Menon, Kevin J Freise
Demonstration of clinical effectiveness of a non-Hodgkin's lymphoma (NHL) treatment generally involves determination of progression-free survival (PFS). However, the long evaluation time of PFS limits its utility to make timely decisions in drug development. Therefore, the objective of this analysis was to determine the relationship between response rates and median PFS in NHL. A database was systematically developed from 513 identified NHL trials reported from 1996 to 2015. Potential predictors of the relationship between response rates and PFS were evaluated, including age, sex, treatment, percentage of treatment-naïve patients, and subtype of NHL...
July 14, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28707331/epstein-barr-virus-lytic-cycle-involvement-in-diffuse-large-b-cell-lymphoma
#13
Melina Cohen, Aldana Georgina Vistarop, Fuad Huaman, Marina Narbaitz, Fernanda Metrebian, Elena De Matteo, María Victoria Preciado, Paola Andrea Chabay
Epstein-Barr virus (EBV)-mediated B cell transformation is achieved predominantly through the action of latent proteins, but recent evidence suggests that lytic EBV replication has also a certain pathogenic role in lymphomagenesis, at least in the early phases of cell transformation. Particularly, in diffuse large B cell lymphoma (DLBCL), the EBV lytic cycle is by and large unexplored, so to disclose lytic cell contribution to lymphomagenesis, our aim was to evaluate viral early and late lytic gene expression in relation to several immune response markers in a series of EBV+ DLBCL from Argentina...
July 14, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28707314/nodular-lymphocyte-predominant-hodgkin-s-lymphoma-in-daily-practice-a-multicenter-experience
#14
Aliihsan Gemici, Ismet Aydogdu, Hatice Terzi, Mehmet Sencan, Alma Aslan, Ali Hakan Kaya, Mehmet Sinan Dal, Meltem Olga Akay, Mehmet Hilmi Dogu, Orhan Ayyildiz, Fahri Sahin, Gulsum Akgun Cagliyan, Mehmet Yilmaz, Zafer Gokgoz, Yusuf Bilen, Cengiz Demir, Omur Gokmen Sevindik, Serdal Korkmaz, Bulent Eser, Fevzi Altuntas
Nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL) is a rare subtype of Hodgkin's lymphoma. In this study, we aimed to investigate the clinical features and therapeutic outcomes of patients with NLPHL who were diagnosed at different institutes in Turkey. We retrospectively reviewed the records of the patients diagnosed with NLPHL. Adult patients who were diagnosed after 2005 with histological confirmation were selected for the study. Forty-three patients were included in the study. Median age of patients was 37...
July 14, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28695659/epstein-barr-virus-negative-extranodal-true-natural-killer-cell-lymphoma-harbouring-a-kdm6a-mutation
#15
Naoko Tsuyama, Reimi Asaka, Akito Dobashi, Satoko Baba, Yuko Mishima, Kyoko Ueda, Masahiko Oguchi, Hideki Tsuji, Kiyohiko Hatake, Kengo Takeuchi
Extranodal natural killer (NK)/T-cell lymphoma, nasal type (ENKTL) is an extranodal aggressive T or NK-cell lymphoma that is characteristically associated with Epstein-Barr virus (EBV) infection and cytotoxic tissue-destructive features. Although ENKTL is described as a distinct entity according to the 2008 WHO classification, a considerable complexity is associated with the differential diagnosis of other T-cell lymphomas with respect to tumour cell origins, locations, and the presence of EBV infection, as well as molecular and cytogenetic abnormalities...
July 10, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28695630/a-pilot-phase-ii-study-of-ofatumumab-monotherapy-for-extranodal-marginal-zone-b-cell-lymphoma-of-the-mucosa-associated-lymphoid-tissue-malt-lymphoma
#16
Barbara Kiesewetter, Ortrun Neuper, Marius E Mayerhoefer, Werner Dolak, Julius Lukas, Ingrid Simonitsch-Klupp, Markus Raderer
These are the final results of the Ofatumumab in MALT lymphoma study (O-MA 1), a pilot phase II trial evaluating the capacity and safety of ofatumumab to induce objective responses in patients with Helicobacter pylori eradication refractory or extragastric MALT lymphoma. Ofatumumab was given at 4 weekly doses (1000 mg) followed by 4 doses at 2-month intervals starting at week 8. According to protocol, a total of 16 patients were recruited (median age 69 years; range 38-85). Thirty one percent (5/16) of patients had primary gastric MALT lymphoma while the remaining 69% (11/16) presented with extragastric manifestations...
July 10, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28685863/efficacy-and-tolerability-of-the-histone-deacetylase-inhibitor-panobinostat-in-clinical-practice
#17
Marc-Andrea Baertsch, Jens Hillengass, Joanna Blocka, Stefan Schönland, Ute Hegenbart, Hartmut Goldschmidt, Marc S Raab
The histone deacetylase inhibitor panobinostat has shown efficacy in phase-II and phase-III trials for multiple myeloma and has recently received market approval in combination with bortezomib and dexamethasone. Here, we retrospectively report our single center experience with panobinostat/bortezomib/dexamethasone (FVD) in a heavily pretreated patient population (n = 24) with a high degree of refractoriness to proteasome inhibitors (PI) and immunomodulatory drugs (IMiD). Median age was 67 years (range 49-87) and the median number of prior therapies was 5 (range 2-17)...
July 7, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28685846/description-of-late-onset-neutropenia-in-indolent-lymphoma-patients-treated-with-bendamustine-plus-rituximab
#18
B Verriere, L Gastaud, E Chamorey, F Peyrade, E Deletie, K Bouredji, D Quinsat, R Schiappa, A Thyss, D Re
Bendamustine (B) associated with rituximab (R) is widely described in literature for the management of patients with chronic lymphoid leukaemia (CLL) and indolent non-Hodgkin lymphoma. Safety data regarding late hematotoxicity such as late onset neutropenia (LON) are scarce. The aim of our study was to assess the incidence and to identify risk factors for LON in patients with indolent non-Hodgkin lymphoma and CLL treated with B and R (B-R). One hundred forty five patients were treated with B-R as first or second line...
July 7, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28681549/ibrutinib-induced-rapid-response-in-chemotherapy-refractory-richter-s-syndrome
#19
LETTER
Angela Fischer, Sara Bastian, Sergio Cogliatti, Ulrich Mey, Jenny Saub, Urs Schanz, Barbara Padberg, Karin Hohloch
No abstract text is available yet for this article.
July 6, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28681529/targeting-complete-response-with-upfront-bortezomib-consolidation-versus-observation-after-the-achievement-of-complete-response-following-autologous-transplantation-for-multiple-myeloma-tuba-study
#20
Hideki Nakasone, Kiriko Terasako-Saito, Teiichi Hirano, Atsushi Wake, Seiichi Shimizu, Naoki Kurita, Etsuko Yamazaki, Kensuke Usuki, Kohei Akazawa, Junya Kanda, Koichiro Minauchi, Go Yamamoto, Shiori Tanimoto, Masaharu Kamoshita, Yasuhisa Yokoyama, Etsuo Miyaoka, Shuichi Ota, Shinichi Kako, Koji Izutsu, Yoshinobu Kanda
Complete response (CR) after treatment for multiple myeloma is associated with superior progression-free survival (PFS). Multiple myeloma patients were prospectively recruited for induction treatment with bortezomib and dexamethasone (BD) followed by autologous hematopoietic cell transplantation (auto-HCT) between 2010 and 2012. If patients did not achieve CR after auto-HCT, BD consolidation therapy was added to target CR. After the BD induction phase (n = 46), greater than or equal to CR was achieved in 4 patients (8%)...
July 6, 2017: Hematological Oncology
journal
journal
28626
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"